Papers (continued)

52. Anker S, Ponikowski P, Clark A, Leyva F, Kemp M, Rauchhaus M, Hooper J, Poole-Wilson P, Coats A. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-693.​



53. Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJS. Hyperleptinaemia in chronic heart failure: relationships with insulin. Eur Heart J 1998;19:1547-1551.


54. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJS. Uric acid in chronic heart failure. A marker of chronic inflammation. Eur Heart J 1998;19:1814-1822.​



55. Leyva F, Godsland I, Ghatei M, Proudler A, Aldis S, Bloom S, Stevenson J. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscl Thromb Vasc Biol 1998;18.​



56. Leyva F, Godsland I, Worthington M, Walton C, Stevenson J. Factors of the metabolic syndrome. Baseline interrelationships in the first follow-up cohort of the HDDRISC study (HDDRISC-1). Arterioscl Thromb Vasc Biol 1998;18:208-214.​



57. Leyva F, Chua T-P, Anker SD, Coats AJS. Uric acid in chronic heart failure: A measure of the anaerobic threshold. Metabolism 1998;47:1-5.​



58. Leyva F, Anker S, Egerer K, Stevenson J, Kox W, Coats A. Hyperleptinaemia in chronic heart failure: Relationships with insulin. Eur Heart J 1998;19:1547-1551.


59. Leyva F, Chua T-P, Anker S, Coats A. Uric acid in chronic heart failure: A measure of the anaerobic threshold. Metabolism 1998;47:1156-1159.​



60. Leyva F, Wingrove C, Godsland I, Stevenson J. The glycolytic pathway to coronary heart disease: A hypothesis. Metabolism 1998;47:657-662.​



61. Godsland I, Leyva F, Walton C, Worthington M, Stevenson J. Associations of smoking, alcohol and physical activity with risk factors for coronary heart disease and diabetes in the first follow-up cohort of the Heart Disease and Diabetes Risk Indicators in a Screened Cohort study (HDDRISC-1). J Int Med 1998;244:33-41.


62. Swan J, Anker S, Walton C, Godsland I, Clark A, Leyva F, Stevenson J, Coats A. Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527-32.​



63. Leyva F, Wingrove C, Felton C, Stevenson JC. Physiological insulinaemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals. Metabolism 1997;46:1137-1139.​



64. Leyva F, Anker S, Swan JW. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-865.​

65. Leyva F, Wingrove C, Felton C, Stevenson J. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals. Metabolism 1997;46:1137-1139.​



 

66. Leyva F, Anker S, Swan J, Godsland I, Wingrove C, Chua T-P, Stevenson J, Coats A. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-865.​



67. Anker S, Leyva F, Poole-Wilson P, Kox W, Stevenson J, Coats A. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 1997;78:39-43.​



68. Godsland I, Bruce R, Leyva F, Worthington M, Walton C, Stevenson J. Insulin and high-density lipoprotein as predictors of coronary heart disease incidence during 11.3 years of follow-up. Eur Heart J 1996;17 (Suppl):38.​



69. McDonagh AJ, Leyva-León FDA, Gawkrodger DJ, Ward AM. Lichen Planus is not commonly a skin marker of Primary Biliary Cirrhosis.Dermatologica, 1990; 180:111
70. Leyva-León FDA, Wright RG, Harrington CIH. E
sophageal Lichen Planus  presenting with dysphagia.. International Journal of Dermatology 1990; 29:354-5​



 

71. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L, ;CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Failure 2001;3:481-489.​



72. Cleland J, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L, for the CARE-HF study Steering Committee and Investigators. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 2005; 7:205-214.​



73. Calvert MJ, Freemantle N, Yao G, Cleland JGF, Billingham L, Daubert J-C, Bryan S, CARE-HF Investigators. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2005; 26:2681-2686.


74. Gras D, Böcker D, Lunati M, Wellens H, Calvert M, Freemantle N, Gervais R, Kappenberger L, Tavazzi L, Erdmann E, Cleland J, Daubert J, for the CARE-HF Study Steering Committee and Investigators. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace 2005; 9:516-522.​



75. Richardson M, Freemantle N, Calvert MJ, Cleland JGF, Tavazzi L, on behalf of the CARE-HF Investigators. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterised by dyssynchrony: a predefined analysis from the CARE-HF trial. Eur Heart J 2005; 28(28).​



76. Cleland J, Freemantle N, Daubert J, Toff W, Leisch F, Tavazzi L. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart 2008; 94:278-283.​



77. Wikstrom G, Lundqvist C, Andren B, Lönnerholm S, Blomström P, Freemantle N, Remp T, Cleland J, on behalf of the CARE-HF study investigators. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J ( In press) 2009.​



78. Bardy G, Lee K, Mark D, Poole J, Toff W, Tonkin A, Smith W, Dorian P, Packer D, White R, Longstreth WJ, Anderson J, Johnson G, Bischoff E, Yallop J, McNulty S, Ray L, Clapp-Channing N, Rosenberg Y, Schron E, HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Eng J Med 2008; 358:1793-1804.​



79. Calvert MJ, Freemantle N, Yao G, Cleland JGF, Billingham L, Daubert J-C, Bryan S, CARE-HF Investigators. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2005;26:2681-2686.​



80. Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L, ;CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Failure 2001;3:481-489.​



81. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. for the Cardiac Resynchronization-Heart Failure (CARE-HF) study investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Eng J Med 2005;352:1539-1549.​

82. Cleland J, Freemantle N, Daubert J, Toff W, Leisch F, Tavazzi L. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study. Heart. 2008;94:278-283.
83. Cleland J, Daubert J, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-1932.​



84. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Johannessen A, Freemantle N, Cleland JG, Tavazzi L, Daubert C., on behalf of the CARE-HF Investigators. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail. 2009;11(7):699-705.


85. Ghio S, Freemantle N, Serio A, Magrini G, Scelsi L, Pasotti M, Cleland J, Tavazzi L. Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (CArdiac REsynchronisation Heart Failure study). Eur J Echocardiogr 2005;7:373-378.​



86. Hoppe U, Casares J, Eiskjaer H, Hagemann A, Cleland J, Freemantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2004;114:18-25.​



87. Hoppe UC. Effect of cardiac resynchronization therapy on the incidence of atrial fibrillation in patients with severe heart failure. J Am Coll Cardiol 2006;114:18-25.


88. Uretsky B. Effects of cardiac resynchronization therapy on mode of death in heart failure (the CArdiac REsynchronization Heart Failure [CARE-HF] trial extension phase). Heart (In press) 2006.​



89. Ellery S, Paul V, Prenner G, Tscheliessnigg K, Merkely B, Malinowski K, Frohlig G, Hintringer F, Bosse O, Diotavelli P, Ravazzi AP, Flathmann H, Danilovic D, Unterberg-Buchwald C, for the OVID Study Investigators. A new endocardial "over-the-wire" or stylet-driven left ventricular lead: first clinical experience. Pacing Clin Electrophysiol 2005;28 (Suppl 1):S31-5.

  • facebook
  • googleplus
  • tbird

Disclaimer: This website is for information only and should not be used for the diagnosis or treatment of medical conditions. All reasonable care has been taken in compiling the information but make no warranty as to its accuracy. You must consult a doctor for the diagnosis and treatment of medical conditions.